Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $541.64, generating $5.15 million. Her remaining stake totaled 324,443 shares, a 2.84% reduction.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, although revenue of $783.3 million missed expectations and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $621, while institutional investors own 94.08% of the company’s stock.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $541.64, for a total transaction of $5,145,580.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at $175,731,306.52. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
United Therapeutics Trading Up 1.0%
Shares of UTHR stock opened at $541.62 on Wednesday. The stock has a market capitalization of $23.23 billion, a P/E ratio of 19.38, a PEG ratio of 2.69 and a beta of 0.49. The firm's 50 day moving average is $510.82 and its 200 day moving average is $539.74. United Therapeutics Corporation has a 12 month low of $409.07 and a 12 month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the business earned $6.41 EPS. United Therapeutics's revenue was down 1.9% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on UTHR. Cantor Fitzgerald reiterated an "overweight" rating on shares of United Therapeutics in a research report on Thursday, October 1st. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $621.00.
Get Our Latest Stock Analysis on UTHR
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in UTHR. BlackRock Inc. bought a new position in United Therapeutics in the 2nd quarter worth about $2,868,735,000. Janus Henderson Group PLC boosted its position in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock valued at $514,016,000 after acquiring an additional 70,829 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of United Therapeutics during the second quarter worth about $450,140,000. Swedbank AB grew its holdings in shares of United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company's stock worth $193,977,000 after purchasing an additional 2,350 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of United Therapeutics by 0.8% in the first quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company's stock worth $183,306,000 after purchasing an additional 2,383 shares during the last quarter. Institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
